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Abstract: The safety of angiotensin II receptor blockers (ARBs) for the treatment of   hypertension 
and cardiovascular and renal diseases has been well documented in numerous randomized clinical 
trials involving thousands of patients. However, recent concerns have surfaced about possible 
links between ARBs and increased risks of myocardial infarction and cancer. Less is known 
about the safety of the direct renin inhibitor aliskiren, which was approved as an antihyperten-
sive in 2007. This article provides a detailed review of the safety of ARBs and aliskiren, with 
an emphasis on the risks of cancer and myocardial infarction associated with ARBs. Safety 
data were identified by searching PubMed and Food and Drug Administration (FDA) Web sites 
through April 2011. ARBs are generally well tolerated, with no known class-specific adverse 
events. The possibility of an increased risk of myocardial infarction associated with ARBs was 
suggested predominantly because the Valsartan Antihypertensive Long-Term Use Evaluation 
(VALUE) trial reported a statistically significant increase in the incidence of myocardial infarc-
tion with valsartan compared with amlodipine. However, no large-scale, randomized clinical 
trials published after the VALUE study have shown a statistically significant increase in the 
incidence of myocardial infarction associated with ARBs compared with placebo or non-ARBs. 
Meta-analyses examining the risk of cancer associated with ARBs have produced conflicting 
results, most likely due to the inherent limitations of analyzing heterogeneous data and a lack 
of published cancer data. An ongoing safety investigation by the FDA has not concluded that 
ARBs increase the risk of cancer. Pooled safety results from clinical trials indicate that aliskiren 
is well tolerated, with a safety profile similar to that of placebo. ARBs and aliskiren are well 
tolerated in patients with hypertension and certain cardiovascular and renal conditions; their 
benefits outweigh possible safety concerns.
Keywords: angiotensin II receptor blocker, renin-angiotensin system, aliskiren, safety, 
  myocardial infarction, cancer
Introduction
The renin-angiotensin system (RAS) consists of a group of hormones, which regu-
lates blood pressure (BP), fluid and electrolyte balance, tissue perfusion, and vascular 
growth.1,2 The RAS plays an important role in the pathophysiology of cardiovascular 
and renal disease,3 and antihypertensive therapies that target the RAS are used in the 
management of hypertension, congestive heart failure, myocardial infarction, stroke, 
high cardiovascular risk, diabetes, and renal failure.2,3 In addition, antihypertensive 
drugs that block the RAS may provide organ protection by acting on local RAS 
  functions in tissues, such as the kidneys, heart, eyes, and brain.2,3
Angiotensin-converting enzyme (ACE) inhibitors (eg, ramipril, captopril,   enalapril, 
fosinopril) were the first class of RAS-blocking agents to become available, and ACE Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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inhibitors have been a cornerstone of   antihypertensive therapy 
for many years.4 Numerous clinical trials have shown that the 
BP-lowering effects of ACE inhibitors   provide cardiovascular 
protection;5 however, ACE inhibitors are associated with 
treatment-related adverse events (AEs) including persistent 
dry cough6,7 and angioedema.8 Both of these AEs are more 
common among black and Asian patients compared with 
white patients,5,8 and cough is also more common among 
women and nonsmokers.7 Cough is typically managed by 
discontinuing ACE inhibitor therapy or by decreasing the 
dose. Antitussives and antihistamines are usually ineffective 
for managing cough; however, in some cases cough may dis-
appear spontaneously.6 Strategies for managing angioedema 
include discontinuation of ACE inhibitor therapy and/or treat-
ment with antihistamines or epinephrine.8 Further, although 
several case reports have suggested a relationship between 
the use of ACE inhibitors and development of cancer, case-
control and longitudinal studies have shown no relationship 
and, in some cases, a protective effect from treatment.9,10
Over the last two decades, several angiotensin II receptor 
blockers (ARBs; eg, losartan, valsartan, telmisartan, olm-
esartan) have been approved as antihypertensive therapies.11 
ARBs provide clinically meaningful benefits for patients with 
cardiovascular and/or renal disease,11 and ARBs generally 
have better tolerability profiles than ACE inhibitors.12 Cough 
is not an AE associated with ARB therapy; however, when 
ARBs are used in combination with ACE inhibitors, there 
is an increased risk of renal dysfunction and hyperkalemia.4 
Over the past several years, concerns have surfaced about 
possible links between ARBs and increased risks of cancer13 
and myocardial infarction.14
Direct renin inhibitors (DRIs) are a new class of anti-
hypertensive agents that target the initial rate-limiting 
step of the RAS.15 Several DRIs have been developed as 
antihypertensive therapies; however, early DRIs, including 
enalakiren, remikiren, and zankiren, had poor bioavailabil-
ity, weak antihypertensive effects, and short durations of 
action.4,15 Aliskiren is the only DRI that is approved by the 
United States Food and Drug Administration (FDA) for 
the treatment of hypertension,16 but several other DRIs are in 
the early stages of clinical development.17,18 In clinical stud-
ies, the AE profile of aliskiren was similar to that of placebo, 
with a lower incidence of cough than ACE inhibitors.15,16
The main purpose of this article is to review the safety of 
ARBs and the DRI aliskiren, including a detailed examination 
of the risks of cancer and myocardial infarction associated 
with ARBs. A brief overview of the RAS and efficacy of 
ARBs and aliskiren is also provided.
Overview of the RAS
Key steps in the RAS are shown in Figure 1.3 Following 
conversion from its precursor prorenin, the aspartate protease 
renin is secreted by granular cells of the juxtaglomerular 
apparatus in the kidney.3,19 The biosynthesis and release of 
renin are key elements in determining the capacity of the 
RAS to regulate BP and respond to fluid changes.3 Renin 
catalyzes the conversion of angiotensinogen to angiotensin I, 
which is the rate-limiting step in the RAS.15 DRIs block 
this step and reduce plasma renin activity.15 ACE catalyzes 
the conversion of angiotensin I to angiotensin II, and ACE 
inhibitors block this step in the RAS.15 Angiotensin II binds 
to angiotensin II type-1 (AT1) receptors, which regulates BP 
via several mechanisms and provides feedback inhibition of 
further release of renin by the kidneys.15 ARBs block the AT1 
receptor, reducing the effects of angiotensin II.4
ARBs and ACE inhibitors may not provide comprehen-
sive suppression of the RAS because they disrupt the negative 
feedback effect of angiotensin II on renin release, resulting in 
an increase in plasma renin concentration and plasma renin 
activity.2,4 ACE inhibitors also increase angiotensin I concen-
trations, and although ACE inhibitors prevent the conversion 
of angiotensin I to angiotensin II, angiotensin II production 
can still occur through non-ACE–dependent pathways 
involving enzymes such as chymase and chymotrypsin-like 
angiotensin-generating enzyme.1,15 In addition, ACE inhibi-
tors block the degradation of bradykinin, and the resulting 
increase in bradykinin concentration may be a factor in the 
development of cough and angioedema associated with these 
agents.15 DRIs may provide more optimal suppression of the 
RAS by interrupting the system at its first regulated step, 
resulting in decreased plasma renin activity.1,2,15
Efficacy of ARBs and the DRI 
aliskiren
In 1995, losartan was the first ARB to receive FDA approval 
as an antihypertensive. Since then, six other ARBs and the 
DRI aliskiren have also been approved for the treatment 
of hypertension; several of these agents also have other 
cardiovascular indications.20 Approved indications, dosing 
information, and dates of FDA approval for the ARBs and 
aliskiren are shown in Table 1.
ARBs
Data from numerous randomized clinical trials indicate that 
ARB therapy is effective in reducing complications related 
to hypertension5 and in slowing or blocking the progression 
of cardiovascular disease.11 As a class of drugs, ARBs have Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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shown clinical benefits for patients with heart failure,   diabetes, 
and chronic kidney disease.5 Pharmacologic and dosing 
differences exist among the seven ARBs approved as antihy-
pertensive agents;11,20 therefore, efficacy and safety results for 
one ARB cannot be extrapolated to other ARBs.20 In general, 
newer ARBs are more effective than losartan in lowering BP 
in patients with hypertension based on the results of head-to-
head comparative studies.11 Recent reviews11,20 have compared 
the efficacy of ARBs vs non-ARBs in different clinical set-
tings. These results are summarized in Table 2.
The DRi aliskiren
The effects of aliskiren on cardiovascular and renal morbidity 
and mortality are currently unknown. However, several out-
comes studies are underway as part of the ASPIRE HIGHER 
clinical trials program, which will help to better define the 
role of direct renin inhibition in clinical practice.1
When administered alone or in combination with other 
agents, including thiazide diuretics, calcium-channel block-
ers, or RAS-blocking drugs (ie, ACE inhibitors or ARBs), 
treatment with aliskiren effectively lowers BP in a variety 
of hypertensive populations (eg, diabetic, obese, elderly).1,21 
In several randomized, double-blind clinical trials, treat-
ment with aliskiren has been associated with positive effects 
on surrogate markers of cardiovascular and renal disease, 
including urinary albumin, N-terminal pro-brain natriuretic 
peptide (NT-proBNP), and left ventricular mass index.22–24 For 
example, in the Aliskiren in the Evaluation of Proteinuria in 
Diabetes (AVOID) trial in patients with hypertension and type 
2 diabetes with nephropathy,22 aliskiren 300 mg/day combined 
with losartan 100 mg/day reduced the mean urinary albumin-
to-creatinine ratio by 20% (95% confidence interval [CI]: 9% 
to 30%; P , 0.001) compared with losartan 100 mg/day plus 
placebo. In the Aliskiren Observation of Heart Failure Treat-
ment (ALOFT) trial23 involving patients with New York Heart 
Association (NYHA) class II to IV heart failure and a history 
of hypertension, addition of aliskiren to an ACE inhibitor (or 
ARB) and β-blocker significantly reduced NT-proBNP con-
centrations compared with placebo. In the Aliskiren in Left 
Ventricular Hypertrophy (ALLAY) trial,24 which included over-
weight patients with hypertension and increased ventricular 
wall thickness, treatment with aliskiren or losartan resulted in 
similar reductions in left ventricular mass index.
In a recent study (Aliskiren Study in Post-MI Patients 
to Reduce Remodeling [ASPIRE]), adding aliskiren to 
standard therapy (ie, statins, beta-blockers, antiplatelets, 
and either ACE inhibitors [given to 90% of the patients] or 
ARBs [10% of the patients]) in the weeks following an acute 
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Figure 1 Overview of the renin-angiotensin system.
Reproduced with permission of the American Society of Nephrology, from ‘The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal 
disease’, Volpe et al, volume 13, supplement 3, 2002; permission conveyed through Copyright Clearance Center, inc.3
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Table 2 Selected outcomes from randomized clinical trials of ARBs
Drug Atherosclerosis Hypertensive  
LVH
2° prevention 
post-MI
Stroke Heart  
failure
Atrial  
fibrillation
Renoprotection
Losartan +/- + 
(LiFe)
- 
(OPTiMAL)
+ 
(LiFe*) 
2° prevent: + 
(LiFe)
+/- 
(eLiTe/ 
eLiTe ii)
1° prevent: + 
(LiFe)
+ 
(ReNAAL, JLiGHT,   
ROAD)
Valsartan + 
(MARVAL-2, 
ViP)
+ + 
(T-VeNTURe, 
VALiANT)
+ 
(Jikei Heart*, 
Kyoto HeART*)
+ 
(Val-HeFT)
1° prevent: + 
(Val-HeFT) 
2° prevent: - 
GiSSi-AF)
+ 
(VALeRiA, SMART,   
HKViN, MARVAL,  
MARVAL-2)
Candesartan + 
(CeNTRO, 
MiT eC)
+ 
(CATCH,  
CASe-J)
- 
(e-COST)
+ 
(SCOPe*) 
1° prevent: - 
(e-COST) 
2° prevent: + 
(e-COST)
+ 
(ReSOLVD,  
CHARM)
2° prevent: - 
(CAPRAF)
+/- 
(DiReCT, 
CeNTRO)
irbesartan + 
(ePAS, iSLAND, 
SiLVHiA)
+ 
(SiLVHiA,  
CViP)
+ 
(i-PReSeRVe)
2° prevent: + +/- 
(iRMA-2, iDNT, 
iMPROVe)
Telmisartan + + 
(ONTARGeT/ 
TRANSCeND)
- 
(TRANSCeND*,†) 
2° prevent: - 
(PROFeSS)
+ 
(RePLACe)
1° prevent: + +/- 
(iNNOVATiON, 
TRANSCeND, 
ONTARGeT,  
DeTAiL)
eprosartan + + 2° prevent: + 
(MOSeS)
+ 
(ADePT)
Olmesartan + 
(eUTOPiA)
-
Reprinted from Advances in Therapy®, volume 27, issue 5, Siragy, ‘Comparing angiotensin II receptors on benefits beyond blood pressure’, pp 257–284, Copyright 2010, 
with permission from Springer.20
Notes: + designates that the study achieved its primary or secondary endpoint(s); - designates that study did not meet its primary or secondary endpoint(s); This table is a 
summary of fully published randomized controlled trial data (ie, no data from single-arm noncomparative trials were considered), with an emphasis on large-scale trials (when 
available). Additional smaller studies were considered in the absence of data from large-scale clinical trials; *Stroke data were not specific to primary or secondary prevention 
in the main analysis; †Stroke was evaluated in a post-hoc analysis, not as a prespecified endpoint.
Abbreviations: ADePT, Addition of the AT1 Receptor Antagonist eprosartan to ACe inhibitor Therapy in Chronic Heart Failure trial; ARBs, angiotensin receptor 
blockers; CAPRAF, Candesartan in the Prevention of Relapsing Atrial Fibrillation; CASe-J, Candesartan Antihypertensive Survival evaluation in Japan; CATCH, Candesartan 
Assessment in the Treatment of Cardiac Hypertrophy; CeNTRO, Candesartan on Atherosclerotic Risk Factors; CHARM, Candesartan in Heart Failure Assessment in 
Reduction of Mortality; CViP, Cardiovascular irbesartan Project; DeTAiL, Diabetics exposed to Telmisartan and enalapril; DiReCT, Diabetic Retinopathy Candesartan Trials; 
E-COST, Efficacy of Candesartan on Outcome in Saitama Trial; ELITE, Evaluation of Losartan in the Elderly; EPAS, Endothelial Protection, AT1 Blockade and Cholesterol-
Dependent Oxidative Stress; EUTOPIA, European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis; GISSI-AF, Gruppo Italiano per lo Studio della 
Sopravvivenza nell’infarto Miocardico–Atrial Fibrillation; HKViN, Hong Kong Study Using Valsartan in igA Nephropathy; iDNT, irbesartan in Diabetic Nephropathy Trial; 
iMPROVe, irbesartan in the Management of Proteinuric Patients at High Risk of Vascular events; iNNOVATiON, incipient to Overt: Angiotensin ii Blocker, Telmisartan, 
investigation on Type 2 Diabetic Nephropathy; i-PReSeRVe, irbesartan in Heart Failure with Preserved Systolic Function; iRMA-2, irbesartan in Microalbuminuria, Type 2 
Diabetic Nephropathy Trial; iSLAND, irbesartan and Lipoic Acid in endothelial Dysfunction; JLiGHT, Japanese Losartan Therapy intended for the Global Renal Protection 
in Hypertensive Patients; LiFe, Losartan intervention For endpoint Reduction in Hypertension; LVH, left ventricular hypertrophy; MARVeL/MARVeL-2, Microalbuminuria 
Reduction with Valsartan; Mi, myocardial infarction; MiT-eC, Media intima Thickness evaluation with Candesartan Cilexetil; MOSeS, Morbidity and Mortality after Stroke, 
eprosartan Compared with Nitrendipine for Secondary Prevention; OPTiMAL, Optimal Trial in Myocardial infarction with the Angiotensin Receptor Blocker Losartan; 
ONTARGeT, Ongoing Telmisartan Alone and in Combination with Ramipril Global endpoint Trial; PROFeSS, The Prevention Regimen for effectively Avoiding Second 
Strokes Trial; ReNAAL, Reduction of endpoints in Non-insulin-dependent Diabetes Mellitus with Angiotensin ii Antagonist Losartan; RePLACe, Replacement of Angiotensin-
Converting enzyme inhibition; ReSOLVD, Randomized evaluation of Strategies for Left Ventricular Dysfunction; ROAD, Renoprotection of Optimal Antiproteinuric Doses; 
SCOPe, Study on Cognition and Prognosis in the elderly; SiLVHiA, Swedish irbesartan Left Ventricular Hypertrophy Versus Atenolol; SMART, Shiga Microalbuminuria 
Reduction Trial; TRANSCeND, Telmisartan Randomized Assessment Study in ACe intolerant Subjects with Cardiovascular Disease; T-VeNTURe, inhibitory effect of 
Valsartan against Progression of Left Ventricular Dysfunction after Myocardial infarction; VALeRiA, Valsartan in Combination with Lisinopril in Hypertensive Patients with 
Microalbuminuria; VALiANT, Valsartan in Acute Myocardial infarction; Val-HeFT, Valsartan Heart Failure Trial; ViP, Valsartan inhibits Platelets.
myocardial infarction gave no further protection against 
ventricular remodeling.25 However, the researchers con-
ducted a post-hoc subgroup analysis and found that patients 
with diabetes (n = 148) were the only subgroup that had a 
borderline interaction in treatment effect. There were more 
AEs in patients assigned to aliskiren, but the total number 
of serious AEs was similar in the two arms. Specifically, AEs 
that occurred at a higher incidence in aliskiren recipients 
compared with placebo recipients included hyperkalemia 
(5.2% vs 1.3%), hypotension (8.8% vs 4.5%), and renal 
dysfunction (2.4% vs 0.8%). Elevations in blood urea nitro-
gen and creatinine were more likely in the aliskiren group, Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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and patients assigned to aliskiren were more likely to have a 
potassium value measured at .5.5 mmol/L or at $6 mmol/L. 
Although these results do not provide support for testing 
the use of aliskiren in a morbidity and mortality trial in this 
population of high-risk postmyocardial infarction patients, 
ASPIRE used a surrogate endpoint and was not powered to 
assess hard clinical outcomes. Aliskiren is currently being 
studied in ongoing outcomes trials of patients with chronic 
heart failure and diabetic nephropathy to assess the role of 
direct renin inhibition in these populations.
Safety of ARBs and the DRI  
aliskiren
Safety of ARBs
As a class of agents, ARBs are well tolerated, with safety 
profiles similar to that of placebo. No class-specific AEs have 
been associated with ARBs.26 ARBs are contraindicated for 
women who are pregnant or may become pregnant because 
of the risk of fetal developmental abnormalities, and ARBs 
are not recommended for women who are breastfeeding.5 
Several antihypertensive drugs have been associated with 
an increased risk of erectile dysfunction (ED); however, 
ARBs have not been observed to increase the risk of ED.5 In 
patients whose renal function may depend on the activity of 
the RAS (eg, patients with severe congestive heart failure), 
treatment with ARBs may be associated with oliguria and/or 
progressive azotemia; rarely, acute renal failure and/or death 
have been reported in these patients. ARBs may also increase 
serum creatinine and/or blood urea nitrogen levels in patients 
with unilateral or bilateral renal-artery stenosis.27,28
ARBs and myocardial infarction
In 2004, an editorial by Verma and Strauss14 raised concerns 
that ARBs may increase the risk of myocardial infarction 
based on results of the Valsartan Antihypertensive Long-
Term Use Evaluation (VALUE) trial,29 which reported a 
statistically significant 19% relative increase in myocardial 
infarction with valsartan compared with the calcium-channel 
blocker amlodipine. Responses to this article from the medi-
cal community were mixed. Several follow-up editorials and 
analyses30–33 cited the need to evaluate the risk of myocardial 
infarction associated with ARBs more systematically and in 
a broader clinical context. However, other publications noted 
that there are possible mechanisms by which ARBs could 
predispose patients to myocardial infarction.12,34
In 2006, Strauss and Hall12 used the term “ARB-MI 
Paradox” to describe the unexpected observation that in some 
clinical trials involving patients at high cardiovascular risk, 
the BP-lowering effects of ARBs did not reduce the risk of 
myocardial infarction compared with placebo, and in some 
cases treatment with ARBs may have increased the risk of 
myocardial infarction. The authors went on to provide a plau-
sible biological mechanism by which ARBs could increase 
the incidence of myocardial infarction by increasing circulat-
ing levels of angiotensin II. Increased angiotensin II levels 
cause up-regulation of angiotensin type-2 (AT2)   receptors. 
While AT2-receptor stimulation may provide beneficial 
effects by mediating vasodilation and nitric oxide release, 
AT2-receptor stimulation may also mediate growth promo-
tion, fibrosis, and hypertrophy, and may have pro-atherogenic 
and pro-inflammatory effects. The authors concluded that 
results from meta-analyses35–38 support the “ARB-MI Para-
dox” because they show that ARBs are associated with an 
increased risk of coronary heart disease events and/or a lack 
of BP-related vascular benefits.
Following the publication of the editorial by Verma and 
Strauss,14 several meta-analyses were performed analyzing 
cardiovascular event outcomes across multiple clinical trials 
involving ARBs. Results of these analyses were mixed, with 
some studies reporting no increased risk of myocardial infarc-
tion associated with ARBs,33,35,36 while other studies12,39 report 
a trend toward increased risk of myocardial infarction with 
ARBs. While meta-analyses can be powerful tools to sum-
marize data across multiple studies, they also have significant 
limitations.40 Identification and selection of studies can be 
biased and availability of results may limit the analyses that 
can be performed. The choice of statistical analysis methods 
(ie, fixed-effects vs random-effects models) can also affect 
the outcome of the meta-analysis. In addition, heterogeneity 
of data between different studies (eg, disease states, follow-up 
time, treatment regimens) may make it difficult to create a 
meaningful integration of results.40 Limitations specifically 
acknowledged in the meta-analyses that evaluated the risk 
of myocardial infarction associated with ARBs included 
heterogeneity of data across studies, limited availability 
of data on the incidence of myocardial infarction, varying 
definitions of myocardial infarction between studies, and the 
potential for confounding effects of different treatments on 
the incidence of myocardial infarction.35,36
Table 3 shows the incidence of myocardial infarction 
reported in randomized clinical trials of ARBs that had 
a mean or median follow-up time of at least 1 year and 
enrolled at least 1000 patients with a range of cardiovas-
cular and renal conditions. Since the publication of the 
Verma and Strauss editorial,14 considerably more data have 
become available on the incidence of myocardial infarction Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 3 Fatal and nonfatal myocardial infarction in clinical trials of ARBs
Trial Year Condition Treatment arms Total patients  
(N)
Follow-up  
(years)
Patients with MI   
n (%)
NAViGATOR44 2010 impaired glucose  
tolerance + CV disease  
or CV risk factors
Placebo 
Valsartan
4675 
4631
5.0 140 (3.0) 
138 (3.0)
KYOTO HeART45 2009 Uncontrolled hypertension Non-ARB therapy 
Valsartan
1514 
1517
3.3 11 (0.7) 
7 (0.5)
ONTARGeT42 2008 Vascular disease or  
high-risk diabetes
Ramipril 
Telmisartan 
Ramipril + telmisartan
8576 
8542 
8502
4.7 413 (4.8) 
440 (5.2) 
438 (5.2)
TRANSCeND43 2008 ACei intolerant + CV disease or 
diabetes with end-organ damage
Placebo 
Telmisartan
2972 
2954
4.7 147 (5.0) 
116 (3.9)
i-PReSeRVe47 2008 Heart failure + LV ejection  
fraction $45%
Placebo 
irbesartan
2061 
2067
4.1 54 (2.6) 
60 (2.9)
PROFeSS48 2008 ischemic stroke Placebo 
Telmisartan
10,186 
10,146
2.5 169 (1.7) 
168 (1.7)
JiKei46 2007 Hypertension, coronary  
artery disease and/or  
heart failure
Non-ARB therapy 
Valsartan
1540 
1541
3.1 19 (1.2) 
17 (1.1)
e-COST41 2005 essential hypertension Conventional therapy 
Candesartan
995 
1053
3.1 23 (2.8)a 
10 (1.2)a
VALUe29 2004 Hypertension risk factors Amlodipine 
Valsartan
7596 
7649
4.2 313 (4.1) 
369 (4.8)
SCOPe55 2003 elderly hypertension Placebo 
Candesartan
2460 
2477
3.7 63 (2.6) 
70 (2.8)
CHARM66,67 2003 Heart failure Placebo 
Candesartan
3796 
3803
3.1 190 (5.0) 
176 (4.6)
CHARM-Added68 2003 CHF + LV ejection  
fraction #40%, being  
treated with ACeis
Placebo 
Candesartan
1272 
1276
3.4 69 (5.4) 
44 (3.4)
CHARM Alternative69 2003 ACei intolerant, symptomatic  
heart failure, + LV ejection  
fraction #40%
Placebo 
Candesartan
1015 
1013
2.8 48 (4.7) 
75 (7.4)
CHARM Preserved70 2003 CHF + LV ejection  
fraction .40%
Placebo 
Candesartan
1509 
1514
3.0 73 (4.8) 
57 (3.8)
VALiANT71,72 2003 Mi + heart failure and/or  
LV dysfunction
Captopril 
Valsartan 
Captopril + valsartan
4909 
4909 
4885
2.1 559 (11.4)b 
587 (12.0)b 
554 (11.3)b
LiFe73 2002 Hypertension + LV  
hypertrophy
Atenolol 
Losartan
4588 
4605
4.8 188 (4.1) 
198 (4.3)
OPTiMAAL74 2002 Mi Captopril 
Losartan
2733 
2744
2.7 379 (13.9) 
384 (14.0)
iDNT75 2001 Diabetic nephropathy Placebo 
irbesartan 
Amlodipine
569 
579 
567
2.6 51 (9.0) 
48 (8.3) 
29 (5.1)
ReNAAL76 2001 Diabetic nephropathy Placebo 
Losartan
762 
751
3.4 68 (8.9) 
50 (6.7)
eLiTe ii77 2000 Heart failure + ejection  
fraction #40%
Captopril 
Losartan
1574 
1578
1.5 28 (1.8) 
31 (2.0)
Notes:  aPercentages reported in the e-COST study are based on the intent-to-treat population (n = 815 for both treatment groups);  bNumber (%) of patients who 
had $1 Mi; Because patients could have more than 1 Mi, the number of investigator-reported Mis was 798 in the captopril group, 796 in the valsartan group, and 756 in the 
captopril + valsartan group.
Abbreviations: ACei, angiotensin-converting enzyme inhibitor; ARB, angiotensin ii receptor blocker; CHARM, Candesartan in Heart Failure Assessment in Reduction of 
Mortality; CHF, congestive heart failure; CV, cardiovascular; E-COST, Efficacy of Candesartan on Outcome in Saitama Trial; ELITE, Evaluation of Losartan in the Elderly; 
iDNT, irbesartan Diabetic Nephropathy Trial; i-PReSeRVe, irbesartan in Heart Failure with Preserved ejection Fraction; LiFe, Losartan intervention for endpoint Reduction 
in Hypertension; LV, left ventricular; Mi, myocardial infarction; NAViGATOR, Nateglinide and Valsartan in impaired Glucose Tolerance Outcomes Research; ONTARGeT, 
Ongoing Telmisartan Alone and in Combination with Ramipril Global endpoint Trial; OPTiMAAL, Optimal Trial in Myocardial infarction with the Angiotensin ii Antagonist 
Losartan; PROFeSS, Prevention Regimen for effectively Avoiding Second Strokes; ReNAAL, Reduction of endpoints in NiDDM with the Angiotensin ii Antagonist Losartan; 
SCOPe, Study on Cognition and Prognosis in the elderly; TRANSCeND, Telmisartan Randomized Assessment Study in ACe intolerant Subjects with Cardiovascular Disease; 
VALiANT, Valsartan in Acute Myocardial infarction; VALUe, Valsartan Antihypertensive Long-Term Use evaluation.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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in patients treated with ARBs. Eight landmark, randomized 
clinical trials involving ARBs have been completed since 
2004. None of these trials has shown a statistically significant 
increase in the incidence of myocardial infarction associ-
ated with ARBs compared with placebo or non-ARB active 
comparators; however, one study (Efficacy of Candesartan on 
Outcome in Saitama Trial [E-COST])41 in Japanese patients 
with essential hypertension reported a statistically significant 
decrease in the risk of myocardial infarction associated with 
candesartan compared with conventional therapy (relative 
risk [RR]: 0.44; 95% CI: 0.21–0.84; P , 0.05).
In the Ongoing Telmisartan Alone and in Combination 
With Ramipril Global Endpoint Trial (ONTARGET) study,42 
which enrolled patients with vascular disease or high-risk dia-
betes, the RR for fatal or nonfatal myocardial infarction was 
1.07 (95% CI: 0.94–1.22) for telmisartan compared with the 
ACE inhibitor ramipril. The RR for myocardial infarction for 
combination therapy with telmisartan and ramipril vs ramipril 
alone was 1.08 (95% CI: 0.94–1.23).42 In the Telmisartan 
Randomized Assessment Study in ACE Intolerant Subjects 
With Cardiovascular Disease (TRANSCEND) study,43 which 
also included patients with diabetes with end-organ damage, 
the incidence of myocardial infarction was 3.9% (116/2954) 
in patients treated with telmisartan and 5.0% (147/2972) in 
patients who received placebo (hazard ratio [HR] for telm-
isartan vs placebo, 0.79; 95% CI: 0.62–1.01; P = 0.059).43 
Results of the Nateglinide And Valsartan in Impaired Glu-
cose Tolerance Outcomes Research (NAVIGATOR) study44 
showed that the event rate for fatal or nonfatal myocardial 
infarction was not significantly different for valsartan 
compared with placebo in patients with impaired glucose 
tolerance and cardiovascular disease or cardiovascular risk 
factors (HR: 0.97; 95% CI: 0.77–1.23; 1-sided P = 0.41; 
2-sided P = 0.83). In the KYOTO HEART study,45 in Japa-
nese patients with uncontrolled hypertension, the HR for 
acute myocardial infarction for valsartan compared with 
non-ARB antihypertensive treatment was 0.65 (95% CI: 
0.2–1.8; P = 0.39). Results from the Jikei Heart Study46 in 
Japanese patients with hypertension, coronary heart disease, 
and/or heart failure showed a HR for new or recurrent acute 
myocardial infarction of 0.90 (95% CI: 0.47–1.74; P = 0.75) 
for valsartan compared with non-ARB therapy.
The Irbesartan in Heart Failure With Preserved Systolic 
Function (I-PRESERVE)47 and Prevention Regimen for 
Effectively Avoiding Second Strokes (PROFESS)48 studies 
did not report statistical analyses for the difference in the 
incidence of myocardial infarction between ARBs   (irbesartan 
and telmisartan, respectively) and placebo; however, the 
incidences of myocardial infarction were numerically similar 
between the ARBs and placebo (Table 3), and no significant 
differences were observed in the HR for death from cardio-
vascular causes. In the I-PRESERVE study,47 the HR for death 
from a cardiovascular cause or nonfatal myocardial infarction 
or stroke was 0.99 (95% CI: 0.86–1.13; P = 0.84) for irbesar-
tan vs placebo, and in the PROFESS study,48 the HR for death 
from cardiovascular causes, recurrent stroke, myocardial 
infarction, or new or worsening heart failure was 0.94 (95% 
CI: 0.87–1.01; P = 0.11) for telmisartan vs placebo.
Two other landmark randomized clinical trials involving 
ARBs are not listed in Table 3 because the published results 
of these studies did not report the incidence of myocardial 
infarction. The Valsartan Heart Failure Trial (Val-HeFT) 
study49 evaluated the effects of valsartan as add-on therapy 
to standard treatment for heart failure in patients with 
NYHA class II, III, or IV heart failure. In this study, treat-
ment with valsartan reduced the incidence of mortality 
and morbidity (defined as cardiac arrest with resuscitation, 
hospitalization for heart failure, or receipt of intravenous 
inotropic or vasodilator therapy for $4 hours) by 13.2% 
compared with placebo (RR: 0.87; 97.5% CI: 0.77–0.97; 
P = 0.009). Results of the Morbidity and Mortality After 
Stroke, Eprosartan Compared With Nitrendipine for 
Secondary Prevention (MOSES) trial50 showed that the 
incidence density ratio for cardiovascular events (including 
myocardial infarction and new cardiac failure) over a mean 
follow-up time of 2.5 years was lower for eprosartan com-
pared with the calcium-channel blocker nitrendipine (0.75; 
95% CI: 0.55–1.02; P = 0.06) in patients with hypertension 
and history of stroke.
ARBs and cancer
A possible link between an increased incidence of cancer 
and the use of antihypertensive drugs, including β-blockers, 
calcium-channel blockers, diuretics, and the alkaloid reser-
pine, has been suggested by several studies.9 However, the 
majority of these possible associations remain unproven or 
highly uncertain.9
Results from animal studies have suggested a possible 
biological mechanism by which ARBs could increase tumor 
cell proliferation and angiogenesis through selective block-
ade of AT1 receptors.51 This selective blockade results in 
increased stimulation of AT2 receptors by angiotensin II. 
Studies in mice52,53 have shown that AT2-receptor blockade 
and gene deletion is associated with decreased expression 
of pro-angiogenic vascular endothelial growth factor and 
increased expression of thrombospondin-1.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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A recent meta-analysis by Sipahi and colleagues13 found 
a modestly increased risk of cancer associated with ARBs. 
Based on an analysis of 5 randomized controlled trials that 
had a follow-up of at least 1 year, the risk of developing new 
cancer was 7.2% (2510/35015) among patients treated with 
ARBs, compared with 6.0% (1602/26575) for controls (RR: 
1.08; 95% CI: 1.01–1.15; P = 0.016). In the trials included 
in this analysis, telmisartan was the study drug for 85.7% 
(n = 30014) of patients who received an ARB. Analysis 
of the trials involving telmisartan showed that the RR for 
development of new cancer in patients treated with telmis-
artan compared with controls was 1.07 (95% CI: 1.00–1.14; 
P = 0.05).
The authors13 also analyzed the results of 5 trials (N = 68 
402) for the occurrence of common types of solid organ 
cancers (ie, breast, lung, and prostate cancer); these results 
are summarized in Table 4. New lung cancer occurred more 
frequently in patients treated with ARBs (0.9% [361/38 
422]) than in control groups (0.7% [195/29 980]; RR: 1.25; 
95% CI: 1.05–1.49; P = 0.01); no significant differences 
were observed for prostate or breast cancers. Based on the 
results of 8 trials that reported cancer deaths, no significant 
difference was observed between ARBs and controls in the 
incidence of cancer deaths (1.8% [n = 959/53 424] for ARBs 
vs 1.6% [n = 639/40 091] for controls; RR: 1.07; 95% CI: 
0.97–1.18; P = 0.183).
In addition to the limitations of meta-analyses discussed 
previously,40 there are several limitations specific to the meta-
analysis performed by Sipahi and colleagues13 that should 
be considered when interpreting these results. The duration 
of follow-up in the trials included in this meta-analysis 
ranged from 1.9–4.8 years. Because cancer is a relatively 
rare occurrence in any time period of less than 5 years, it 
has been argued that the duration of follow-up in these tri-
als was too short to draw any meaningful conclusions about 
the development of new cancers.54 In addition, development 
of cancer is a relatively rare AE, and rare AEs are often not 
analyzed statistically in randomized clinical trials because of 
small sample sizes; this problem can persist even when data 
are pooled.40 It is also important to note that these results are 
based on post-hoc analyses, and the primary studies were 
not designed to test for the development of cancer.13 Further, 
it is not appropriate to draw conclusions about a possible 
class effect for all ARBs based on results of this meta-
analysis because telmisartan was the study drug in 85.7% 
of patients who received ARBs. Because the different ARBs 
have unique pharmacologic and dosing properties,20 results 
heavily weighted for telmisartan cannot be extrapolated 
to the entire class of medications. As noted by Sipahi and 
colleagues, publication bias was also a significant limiting 
factor in this meta-analysis. There is a lack of published and/
or publicly available information on the incidence of cancer 
observed in clinical trials of ARBs.20 Specifically, many large 
trials (eg, VALUE,29 Study on Cognition and Prognosis in 
the Elderly [SCOPE]55) did not collect cancer data or did 
not provide their cancer data to the authors of this study; of 
60 trials identified as meeting the inclusion criteria for this 
analysis, data on cancer incidence and/or cancer deaths were 
only available from nine trials.13 In addition, the authors of 
this meta-analysis did not have access to patient-level data 
to determine whether factors such as age, sex, and smoking 
status may have influenced the results.13
Subsequently, a second meta-analysis56 was performed 
to assess whether there is an increased risk of cancer associ-
ated with antihypertensive therapy. Results of this analysis56 
refuted the results of the Sipahi study.13 In their meta-analysis, 
Bangalore and colleagues identified 70 randomized clinical 
trials of antihypertensive agents (ARBs, ACE inhibitors, 
calcium-channel blockers, and diuretics) involving 324,168 
patients and found no increased risk of cancer associated 
with ARBs compared with placebo or other antihyperten-
sive controls using random-effects and fixed-effect models 
(Table 5).56   However, in a fixed-effect model, the combina-
tion of ARBs with ACE inhibitors was associated with an 
increased cancer risk compared with placebo and compared 
with ARBs (Table 5). When the results of individual trials of 
ARBs were evaluated for cancer risk and cancer-related death, 
ARBs did not differ significantly vs comparators (Figure 2). 
In addition, results did not differ for telmisartan compared 
with other ARBs.
A third meta-analysis,57 conducted by the ARB Trial-
ists Collaboration, evaluated the incidence of cancer in 
15 long-term, randomized, controlled trials that involved 
138,769 patients at high risk for cardiovascular disease who 
received ARBs (telmisartan, irbesartan, valsartan, candesartan, 
or   losartan). In this analysis, the trials included were required to 
have an average follow-up time of at least 12 months. Similar to 
the Bangalore meta-analysis,56 no increased risk of cancer with 
ARBs was identified; the cancer incidence in the 15 trials was 
6.16% (4549/73,808) in the ARB groups vs 6.31% (3856/61 
106) in the control groups (odds ratio [OR]: 1.00; 95% CI: 
0.95–1.04; P = 0.886). In addition, no increased cancer risk 
was observed when evaluating the individual ARBs, and no 
differences were observed in the incidences of lung, prostate, 
or breast cancers between ARBs and controls. This analysis 
also examined cancer risk of ARB/ACE inhibitor combinations Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 4 incidence of solid organ cancers reported in a meta-analysis of randomized controlled trials of ARBs
Cancer type ARB Control RR (95% CI) I2 P value
Lung cancer
All available trials
  LiFe 29/4605 (0.6%) 12/4588 (0.3%) 2.41 (1.23–4.71) 0.01
  CHARM-Overall 31/3803 (0.8%) 25/3796 (0.7%) 1.24 (0.73–2.09) 0.43
  TRANSCeND 35/2954 (1.2%) 27/2972 (0.9%) 1.30 (0.79–2.15) 0.30
  ONTARGeT 229/17 044 (1.3%) 101/8576 (1.2%) 1.14 (0.90–1.44) 0.27
  PROFeSS 37/10 016 (0.4%) 30/10 048 (0.3%) 1.24 (0.77–2.00) 0.39
  Meta-analysis 361/38 422 (0.9%) 195/29 980 (0.7%) 1.25 (1.05–1.49) 6.6% 0.01
with background ACe-inhibitor treatment
  CHARM-Added 12/1276 (0.9%) 7/1272 (0.6%) 1.71 (0.68–4.33) 0.26
    ONTARGeT (telmisartan + ramipril vs ramipril) 129/8502 (1.5%) 101/8576 (1.2%) 1.29 (0.99–1.67) 0.055
  Meta-analysis 141/9778 (1.4%) 108/9848 (1.1%) 1.32 (1.03–1.69) 0% 0.031
without background ACe-inhibitor treatment
  LiFe 29/4605 (0.6%) 12/4588 (0.3%) 2.41 (1.23–4.71) 0.01
  TRANSCeND 35/2954 (1.2%) 27/2972 (0.9%) 1.30 (0.79–2.15) 0.30
    ONTARGeT (telmisartan vs ramipril) 100/8542 (1.2%) 101/8576 (1.2%) 0.99 (0.76–1.31) 0.97
  CHARM-Alternative 10/1013 (1.0%) 3/1015 (0.3%) 3.34 (0.93–12.10) 0.066
  Meta-analysis 174/17 114 (1.0%) 143/17 151 (0.8%) 1.50 (0.93–2.41) 65% 0.097
Prostate cancer*
All available trials
  LiFe 58/2118 (2.7%) 42/2112 (2.0%) 1.38 (0.93–2.04) 0.11
  CHARM-Overall 32/2617 (1.2%) 27/2582 (1.0%) 1.17 (0.70–1.95) 0.55
  TRANSCeND 35/1674 (2.1%) 27/1705 (1.6%) 1.32 (0.80–2.17) 0.27
  ONTARGeT 275/12 544 (2.2%) 128/6245 (2.0%) 1.07 (0.87–1.32) 0.53
  PROFeSS 36/6455 (0.6%) 32/6418 (0.5%) 1.12 (0.70–1.80) 0.64
  Meta-analysis 436/25 408 (1.7%) 256/19 062 (1.3%) 1.15 (0.99–1.34) 0% 0.076
with background ACe-inhibitor treatment
  CHARM-Added 7/1006 (0.7%) 9/1000 (0.9%) 0.77 (0.29–2.07) 0.61
    ONTARGeT (telmisartan + ramipril vs ramipril) 141/6252 (2.3%) 128/6245 (2.0%) 1.10 (0.87–1.39) 0.43
  Meta-analysis 148/7258 (2.0%) 137/7245 (1.9%) 1.08 (0.86–1.36) 0% 0.52
without background ACe-inhibitor treatment
  LiFe 58/2118 (2.7%) 42/2112 (2.0%) 1.38 (0.93–2.04) 0.11
  TRANSCeND 35/1674 (2.1%) 27/1705 (1.6%) 1.32 (0.80–2.17) 0.27
    ONTARGeT (telmisartan vs ramipril) 134/6292 (2.1%) 128/6245 (2.0%) 1.04 (0.82–1.32) 0.75
  CHARM-Alternative 8/691 (1.2%) 3/691 (0.4%) 2.67 (0.71–10.01) 0.15
  Meta-analysis 235/10 775 (2.2%) 200/10 753 (1.9%) 1.17 (0.97–1.41) 9.6% 0.10
Breast cancer†
All available trials
  LiFe 37/2487 (1.5%) 36/2476 (1.5%) 1.02 (0.65–1.61) 0.92
  CHARM-Overall 17/1186 (1.4%) 17/1214 (1.4%) 1.02 (0.52–2.00) 0.95
  TRANSCeND 20/1280 (1.6%) 17/1267 (1.3%) 1.16 (0.61–2.21) 0.64
  ONTARGeT 60/4500 (1.3%) 34/2331 (1.5%) 0.91 (0.60–1.39) 0.67
  PROFeSS 20/3561 (0.6%) 15/3630 (0.4%) 1.36 (0.70–2.65) 0.37
  Meta-analysis 154/13 014 (1.2%) 119/10 918 (1.1%) 1.04 (0.82–1.32) 0% 0.74
with background ACe-inhibitor treatment‡
    ONTARGeT (telmisartan + ramipril vs ramipril) 33/2250 (1.5%) 34/2331 (1.5%) 1.00 (0.61–1.66) .0.99
without background ACe-inhibitor treatment
  LiFe 37/2487 (1.5%) 36/2476 (1.5%) 1.02 (0.65–1.61) 0.92
  TRANSCeND 20/1280 (1.6%) 17/1267 (1.3%) 1.16 (0.61–2.21) 0.64
    ONTARGeT (telmisartan vs ramipril) 27/2250 (1.2%) 34/2331 (1.5%) 0.83 (0.50–1.36) 0.45
  CHARM-Alternative 5/322 (1.6%) 4/324 (1.2%) 1.26 (0.34–4.64) 0.73
  Meta-analysis 89/6339 (1.2%) 91/6398 (1.4%) 0.99 (0.74–1.32) 0% 0.93
Reprinted from The Lancet Oncology, volume 11, issue 7, Sipahi et al, ‘Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials’,   
pp 627–636, Copyright 2010, with permission from elsevier.13
Notes: *Analysis limited to men; †Analysis limited to women, all breast cancers were assumed to have occurred in women; ‡Breast cancer data were not available for the 
CHARM-Added trial.
Abbreviations: ACe, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CHARM, Candesartan in Heart Failure Assessment in Reduction of Mortality; 
CI, confidence interval; LIFE, Losartan Intervention for Endpoint Reduction in Hypertension; ONTARGET, Ongoing Telmisartan Alone and in Combination with Ramipril 
Global endpoint Trial; PROFeSS, Prevention Regimen for effectively Avoiding Second Strokes; RR, risk ratio; TRANSCeND, Telmisartan Randomized Assessment Study in 
ACe intolerant Subjects with Cardiovascular Disease.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 5 Risk of cancer and cancer-related death with ARBs
Comparator Cancer odds ratios, 95% CI Cancer-related death odds ratios, 95% CI
Direct  
comparison 
(Peto OR)
Multiple  
comparisons 
(fixed effect)
Multiple  
comparisons  
(random effects)
Direct  
comparison  
(Peto OR)
Multiple  
comparisons 
(fixed effect)
Multiple  
comparisons 
(random effects)
ACeis 0.96 (0.86–1.06) 0.99 (0.92–1.07) 0.99 (0.84–1.09) 0.97 (0.83–1.14) 0.95 (0.83–1.07) 0.93 (0.80–1.08)
β Blockers 0.89 (0.76–1.04) 0.96 (0.88–1.05) 0.96 (0.82–1.08) 0.97 (0.74–1.26) 0.93 (0.80–1.08) 0.97 (0.80–1.19)
CCBs 1.18 (1.04–1.33) 1.04 (0.96–1.11) 1.03 (0.92–1.16) 1.19 (0.40–3.56) 0.96 (0.82–1.10) 0.96 (0.78–1.16)
Diuretics 1.01 (0.06–16.67) 0.99 (0.90–1.09) 0.98 (0.82–1.25) – 0.98 (0.84–1.13) 0.97 (0.78–1.17)
Controls 1.05 (0.76–1.47) 0.96 (0.74–1.22) 0.96 (0.70–1.37) 1.30 (0.75–2.27) 1.08 (0.79–1.44) 1.08 (0.81–1.40)
ACeis + ARBs 1.10 (0.99–1.22) 1.13 (1.03–1.24) 1.14 (0.93–1.33) 1.07 (0.90–1.27) 1.09 (0.94–1.27) 1.06 (0.87–1.30)
Reprinted from The Lancet Oncology, volume 12, issue 1, Bangalore et al, ‘Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 
324 168 participants from randomised trials’, pp 65–82, Copyright 2011, with permission from elsevier.56
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium-channel blocker; CI, confidence interval; OR, odds ratio.
vs ACE inhibitors alone, ARBs alone vs ACE inhibitors 
alone, and ARBs vs placebo/controls without ACE inhibitors. 
No increased risk of cancer was observed in any of these 
overall comparisons (Figure 3). A nominal increase in cancer 
risk was observed with the ARB/ACE inhibitor combination 
in one trial (ONTARGET) but a reduced cancer risk was 
observed with this combination in another (VALIANT). 
Thus, the authors concluded that the increased risk of cancer 
observed with the ARB/ACE inhibitor combination may be 
due to chance and that further study is needed to resolve this 
question.
Because cancer was not a prespecified outcome in most 
randomized clinical trials involving ARBs, the amount of 
published information discussing cancer rates in individual 
randomized clinical trial results is limited. The authors of 
both the Sipahi13 and Bangalore56 studies searched FDA 
  dockets for information on cancer submitted to the FDA 
during drug approval processes, labeling changes, and 
FDA meeting minutes. The authors of the Bangalore study56 
also contacted authors and study investigators via email to 
obtain additional unpublished cancer data. The authors of 
the ARB Trialists analysis57 had access to individual data 
for several studies with prespecified methods for cancer 
identification and tabulated cancer outcomes data for the 
other trials.
The Bangalore56 and ARB Trialists57 meta-analyses were 
more robust than the Sipahi meta-analysis13 because more 
trials were included and multiple comparison analysis was 
performed on the network of different treatments. However, 
the authors of the Bangalore study56 acknowledge several 
limitations including the possibility that the survival ben-
efit associated with antihypertensive therapy compared 
with placebo may have introduced a “survival bias” that 
increased the incidence of cancer in active treatment groups. 
For all the meta-analyses, there may have been other con-
founding variables that are nearly impossible to measure, 
such as exposure to radiation or carcinogens. None took 
into consideration the incidence of a specific cancer in 
the general population. In addition, the selection criteria 
used to include trials in these meta-analyses could have 
influenced the findings (ie, certain trials when put together 
could increase, decrease, or have no effect on cancer risk). 
Moreover, results are limited by the short-term nature of 
most trials and the relatively short duration of exposure 
to the drugs in question to determine cancer risk. Finally, 
publication bias, issues with heterogeneity, and availability 
of data can affect any meta-analysis.
Several population-based studies have evaluated the 
association between antihypertensive treatment and cancer 
over the years. A recent analysis by Huang and colleagues 
specifically investigated the association between ARBs and 
the occurrence of new cancers in 109,002 patients with 
newly diagnosed hypertension.58 Patients were identified 
from a random sample of 1 million individuals of mostly 
Chinese ethnicity using the Taiwanese National Health 
Insurance database. Over an average follow-up period of 
5.7 years, a total of 9067 cases of new cancer were reported 
with a significantly lower occurrence among patients 
receiving ARBs than not receiving ARBs (3082 vs 5985; 
P , 0.001). This was the case after adjusting for age, sex, 
comorbidities, and medications for hypertension control 
(HR: 0.66; 95% CI: 0.63–0.68; P , 0.001). Consistent 
results were observed regardless of ARB and for all types 
of cancer, although conclusions regarding cause and effect 
cannot be established.
Based on the results of the Sipahi study, the FDA initiated 
a safety review of ARBs.59 In July 2010, the FDA issued a 
communication stating that their results to date indicated 
that the benefits of ARB therapy outweighed the risks. The 
FDA did not conclude that ARBs increase the risk of cancer 
but they will continue their analysis and update the public 
as more data become available.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
308
Siragy
OR (95% CI)
Favors ARBs Favors control
ARBs n/N Control n/NW eight (%)
OR (95% CI) ARBs n/N Control n/NW eight (%)
A
B
Telmisartan
Non-telmisartan ARBs
ONTARGET (vs ACEi) 1.04 (0.94–1.16) 762/8542
1/197
59/1013
55/1024
5/402
7/1541
12/1517
358/4605
4/751
4/391
510/7649
1022/19 812
3108/49 996
200/8542
200/8542
71/10146
66/2954
537/30 184
23/1013 18/1015
4/722
17/1024
52/2067 52/2061
23/1025
3/720
13/1136 6/579
4/402 1/206
5/1517 5/1514
115/4605 111/4588
42/2744 42/2733
2/751
1/183 2/183
1/762
67/4885
67/4885
0/197 0/196
42/4862
55/4879
0/180 0/180
405/26807
942/56 991 952/57 291
368/27055
0/1053 0/995
7/722
735/8576 23.56
24.81
11.11
7.03
66.50
0.03
1.92
0.24
1.84
0.11
0.24
0.43
0.12
0.12
10.83
17.62
33.50
100.00
100.00
21.29
23.24
7.72
6.92
59.17
2.17
0.38
2.12
5.47
0.91
0.24
0.54
4.47
0.16
0.16
6.50
5.82
0.00
0.00
0.00
40.83
11.90
824/8502
204/2972
340/10 186
2103/30 236
1/196
59/1015
7/720
58/1025
2/206
7/1540
13/1514
320/4588
3/762
3/381
591/7596
1064/19 543
3167/49 779
204/8576
242/8502
73/10186
65/2972
584/30 236
762/8542
326/10 146
236/2954
2086/30 184
0.91 (0.82–1.01)
0.96 (0.82–1.12)
1.18 (0.97–1.43)
0.99 (0.93–1.06)
0.99 (0.06–15.96)
1.00 (0.69–1.45)
1.00 (0.35–2.86)
1.00 (0.35–2.86)
1.27 (0.26–6.12)
0.95 (0.65–1.38)
0.92 (0.42–2.02)
1.12 (0.96–1.31)
1.35 (0.31–5.97)
1.30 (0.29–5.75)
0.85 (0.75–0.96)
0.95 (0.87–1.04)
0.98 (0.93–1.03)
0.98 (0.81–1.20)
0.82 (0.68–0.99)
0.98 (0.70–1.36)
1.02 (0.72–1.45)
0.92 (0.82–1.03)
1.29 (0.69–2.38)
1.33 (0.30–5.86)
0.74 (0.39–1.38)
1.00 (0.68–1.47)
0.91 (0.35–2.36)
1.87 (0.29–11.96)
1.00 (0.29–3.45)
1.03 (0.79–1.35)
1.00 (0.65–1.53)
1.98 (0.21–19.05)
0.51 (0.05–4.95)
1.22 (0.85–1.74)
1.58 (1.08–2.31)
1.11 (0.97–1.28)
0.99 (0.91–1.09)
Excluded
Excluded
Excluded
ONTARGET (vs ACEi + ARB)
PROFESS
TRANSCEND
Subtotal:
ALPINE
CHARM Alternative
GISSI-AF
HIJ-CREATE
IRMA-2
Jikea
Kyoto
LIFE
RENAAL
TROPHY
VALUE
I2 = 54.4%, P = 0.087
Telmisartan
ONTARGET (vs ACEi)
ONTARGET (vs ACEi + ARB)
PROFESS
TRANSCEND
Subtotal:I2 = 0.0%, P = 0.496
Subtotal:
Overall:
Interaction:
I2 = 0.0%, P = 0.586
Non-telmisartan ARBs
I-PRESERVE
CHARM Alternative
GISSI-AF
HIJ-CREATE
IRMA-2
IDNT (overall)
Kyoto
LIFE
OPTIMAL
RENAAL
Suzuki
ALPINE
E-COST
ROAD
VALIANT (vs ACEi)
VALIANT (vs ACEi + ARB)
Subtotal: I2 = 0.0%, P = 0.817
I2 = 10.3%, P = 0.338
P = 0.46
Overall:
Interaction:
I2 = 0.0%, P = 0.591
P = 0.04
0.1 11 0
Favors ARBs Favors control
0.1 11 0
Figure 2 ARBs and cancer risk A) and cancer-related death B), stratified by ARB type (telmisartan or other).
Reprinted from The Lancet Oncology, volume 12, issue 1, Bangalore et al, ‘Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 
324 168 participants from randomised trials’, pp 65–82, Copyright 2011, with permission from elsevier.56
Note: The size of the data marker represents the weight of each trial. CHARM-added and Val-HeFT trials were excluded because they were regarded as ACei and ARB 
combination trials.
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ALPINE, Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation; ARBs, angiotensin 
receptor blockers; CHARM, Candesartan in Heart failure Assessment in Reduction of Mortality; CI, confidence interval; E-COST, Efficacy of Candesartan on Outcome in Saitama 
Trial; GiSSi-AF, Gruppo italiano per lo Studio della Sopravvivenza nell’infarto Miocardico–Atrial Fibrillation; HiJ-CReATe, Heart institute of Japan Candesartan Randomized Trial 
for evaluation in Coronary Artery Disease; iDNT, irbesartan Diabetic Nephropathy Trial; i-PReSeRVe, irbesartan in Heart Failure with Preserved Systolic Function;  iRMA-2, 
irbesartan in Microalbuminuria, Type 2 Diabetic Nephropathy Trial; LiFe, Losartan intervention For endpoint Reduction in Hypertension; OPTiMAL, Optimal Trial in Myocardial 
infarction with the Angiotensin Receptor Blocker Losartan; ONTARGeT, Ongoing Telmisartan Alone and in Combination with Ramipril Global endpoint Trial; OR, odds 
ratio; PROFeSS, The Prevention Regimen For effectively Avoiding Second Strokes Trial; ReNAAL, Reduction of endpoints in Non-insulin-dependent Diabetes Mellitus with 
Angiotensin ii Antagonist Losartan; ROAD, Renoprotection of Optimal Antiproteinuric Doses; TRANSCeND, Telmisartan Randomized Assessment Study in ACe intolerant 
Subjects with Cardiovascular Disease; TROPHY, Trial of Prevention of Hypertension; VALiANT, Valsartan in Acute Myocardial infarction; VALUe, Valsartan Antihypertensive 
Long-Term Use evaluation.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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ONTARGET*
PROFESS
ACTIVE I
I-PRESERVE
Val-HeFT
VALIANT
CHARM-Added*
667/7966 (8.37%)
102/3687 (2.77%)
186/2720 (6.84%)
40/531 (7.53%)
130/2506 (5.19%)
57/4862 (1.17%)
69/1198 (5.76%)
606/8029 (7.55%)
128/3726 (3.44%)
200/2724 (7.34%)
27/502 (5.38%)
143/2493 (5.74%)
83/4879 (1.70%)
51/1197 (4.26%)
1.12 (1.00–1.26)
0.80 (0.61–1.04)
0.93 (0.75–1.14)
1.43 (0.87–2.37)
0.90 (0.70–1.15)
0.69 (0.46–0.96)
1.37 (0.95–1.99)
Total 1251/23470 (5.33%) 1238/23550 (5.26%)1 .01 (0.94–1.10)
ARB + ACEi better
A No. events/No. randomized
ARB + ACEi ACEi OR (95% Cl)D ifference Heterogeneity
P-value for
ACEi better
0.723 0.008
0.41 .0 1.6
OR (95% Cl)
2.2
TRANSCEND*
PROFESS
ACTIVE I
I-PRESERVE
IDNT
VALUE
CHARM-Alternative*
200/2806 (7.13%)
224/6329 (3.54%)
150/1798 (8.34%)
90/1532 (5.87%)
25/577 (4.33%)
669/7622 (8.78%)
49/951 (5.15%)
166/2826 (5.87%)
212/6322 (3.35%)
168/1774 (9.47%)
109/1559 (6.99%)
31/563 (5.51%)
782/7576 (10.32%)
47/943 (4.98%)
1.23 (0.99–1.52)
1.06 (0.87–1.28)
0.87 (0.69–1.10)
0.83 (0.62–1.11)
0.78 (0.45–1.33)
0.84 (0.75–0.93)
1.04 (0.69–1.56)
SCOPE
DIRECT(all)
TROPHY
LIFE
195/2477 (7.87%)
47/2610 (1.80%)
17/395 (4.30%)
343/4605 (7.45%)
180/2460 (7.32%)
28/2614 (1.07%)
14/386 (3.63%)
316/4588 (6.89%)
1.08 (0.88–1.34)
1.69 (1.06–2.71)
1.20 (0.58–2.46)
1.09 (0.94–1.27)
2009/31702 (6.34%) 2053/31611 (6.49%)0 .97 (0.91–1.04) Total
ARB + ACEi better
C No. events/No. randomized
ARB  Placebo OR (95% Cl)D ifference Heterogeneity
P-value for
ACEi better
0.400 0.007
0.41 .0 1.6
OR (95% Cl)
2.2
ONTARGET*
PROFESS
ACTIVE
I-PRESERVE
VALIANT
630/7999 (7.88%)
224/6329 (3.54%)
150/1796 (8.34%)
90/1532 (5.87%)
86/4885 (1.76%)
606/8029 (7.55%)
128/3726 (3.44%)
200/2724 (7.34%)
27/502 (5.38%)
83/4879 (1.70%)
1.05 (0.93–1.18)
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1.15 (0.92–1.43)
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1.04 (0.76–1.40)
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B No. events/No. randomized
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ACEi better
0.185 0.956
1.01 .6
OR (95% Cl)
2.2
Figure 3 incidence of cancer with A) ARB/ACe inhibitor combination vs ACe inhibitor alone, B) ARB alone vs ACe inhibitor alone, and C) ARB vs placebo/control with 
no ACe inhibitor.
Reprinted from the Journal of Hypertension, volume 29, issue 4, the ARB trialists collaboration, ‘effects of telmisartan, irbesartan, candesartan, and losartan on cancers in 15 
trials enrolling 138 769 individuals’, pp 623–635, Copyright 2011, with permission from wolters Kluwer Health.57
Notes: in the LiFe study, atenolol was the control. *included patients who were free of cancer at baseline.
Abbreviations: ACei, angiotensin-converting enzyme inhibitor; ACTiVe, Atrial Fibrillation Clopidogrel Trial with irbesartan for Prevention of Vascular events; ARB, 
angiotensin receptor blocker; CHARM, Candesartan in Heart failure Assessment in Reduction of Mortality; CI, confidence interval; DIRECT, Diabetic Retinopathy Candesartan 
Trials; iDNT, irbesartan in Diabetic Nephropathy Trial; i-PReSeRVe, irbesartan in Heart Failure with Preserved Systolic Function; LiFe, Losartan intervention For endpoint 
Reduction in Hypertension; ONTARGeT, Ongoing Telmisartan Alone and in Combination with Ramipril Global endpoint Trial; OR, odds ratio; PROFeSS, The Prevention 
Regimen for effectively Avoiding Second Strokes Trial; SCOPe, Study on Cognition and Prognosis in the elderly; TRANSCeND, Telmisartan Randomized Assessment Study 
in ACe intolerant Subjects with Cardiovascular Disease; TROPHY, Trial of Prevention of Hypertension; Val-HeFT, Valsartan Heart Failure Trial; VALiANT, Valsartan in 
Acute Myocardial infarction; VALUe, Valsartan Antihypertensive Long-Term Use evaluation.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 6 Adverse events of special interest from randomized controlled trials of aliskiren
A. Short-term placebo-controlled studies
Adverse event  
of special interest
Placebo  
n = 1555
Aliskiren  
150 mg  
n = 1246
Aliskiren  
300 mg  
n = 1363
Aliskiren/ 
HCTZ  
n = 1464
HCT  
n = 555
Aliskiren/ 
ARB  
n = 624
ARB  
n = 1069
Angioedema/urticaria 8 (0.5) 2 (0.2) 4 (0.3) 1 (0.1) 1 (0.2) 0 3 (0.3)
Cough 11 (0.7) 18 (1.4) 10 (0.7) 20 (1.4) 4 (0.7) 3 (0.5) 4 (0.4)
Rash 6 (0.4) 3 (0.2) 3 (0.2) 3 (0.2) 4 (0.7) 0 1 (0.1)
Hypotension 34 (2.2) 16 (1.3) 37 (2.7) 54 (3.7) 19 (3.4) 16 (2.6) 25 (2.3)
Hyperkalemia 1 (0.1) 0 1 (0.1) 0 1 (0.2) 0 0
Peripheral edema 12 (0.8) 6 (0.5) 18 (1.3) 13 (0.9) 7 (1.3) 1 (0.2) 5 (0.5)
Renal dysfunction 2 (0.1) 7 (0.6) 3 (0.2) 1 (0.1) 0 2 (0.3) 2 (0.2)
Diarrhea 19 (1.2) 18 (1.4) 27 (2.0) 24 (1.6) 10 (1.8) 10 (1.6) 17 (1.6)
Gastrointestinal  
bleeding or ulceration
2 (0.1) 1 (0.1) 1 (0.1) 3 (0.2) 1 (0.2) 1 (0.2) 1 (0.1)
B. Long-term active-controlled studies
Adverse event of  
special interest
Aliskiren alone 
(all doses)  
n = 1594
Aliskiren  
150 mg 
n = 871
Aliskiren  
300 mg 
 n = 723
All aliskiren*  
n = 1749
ARB  
n = 154
ACEi  
n = 866
HCTZ  
n = 557
Angioedema/urticaria 7 (0.4) 4 (0.5) 3 (0.4) 8 (0.5) 0 4 (0.5) 2 (0.4)
Cough 62 (3.9) 38 (4.4) 24 (3.3) 64 (3.7) 3 (1.9) 104 (12.0) 22 (3.9)
Rash 14 (0.9) 6 (0.7) 8 (1.1) 15 (0.9) 1 (0.6) 4 (0.5) 5 (0.9)
Hypotension 121 (7.6) 73 (8.4) 48 (6.6) 135 (7.7) 7 (4.5) 79 (9.1) 36 (6.5)
Hyperkalemia 2 (0.1) 1 (0.1) 1 (0.1) 2 (0.1) 1 (0.6) 2 (0.2) 0
Peripheral edema 76 (4.8) 41 (4.7) 35 (4.8) 79 (4.5) 2 (1.3) 34 (3.9) 34 (6.1)
Renal dysfunction 6 (0.4) 2 (0.2) 4 (0.6) 6 (0.3) 1 (0.6) 3 (0.3) 2 (0.4)
Diarrhea 74 (4.6) 52 (6.0) 22 (3.0) 81 (4.6) 9 (5.8) 33 (3.8) 17 (3.1)
Gastrointestinal  
bleeding or ulceration
3 (0.2) 1 (0.1) 2 (0.3) 5 (0.3) 1 (0.6) 2 (0.2) 2 (0.4)
Reprinted from the Journal of Clinical Hypertension, volume 12, issue 10, white et al, ‘Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical 
experience in more than 12,000 patients with hypertension’, pp 765–775, Copyright 2010, with permission from John wiley and Sons.16
Notes: *“All aliskiren” includes patients who have received aliskiren as monotherapy or in combination with other antihypertensive agents. Data are number (%) of patients. 
Data are presented according to the treatment group to which patients were randomized, irrespective of doses used during any titration periods.
Abbreviations: ACei, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; HCTZ, hydrochlorothiazide.
Safety of aliskiren
The clinical studies conducted to date with aliskiren have 
shown this agent to be well tolerated with an AE profile 
similar to that of placebo, although the treatment duration 
has been too short to evaluate potential risk for myocardial 
infarction or cancer. The most commonly reported AEs were 
fatigue, headache, dizziness, diarrhea, nasopharyngitis, and 
back pain.15 Because aliskiren does not inhibit or induce cyto-
chrome P450 isoenzymes, it has relatively few interactions 
with other drugs.15 Aliskiren is contraindicated for women 
who are pregnant or may become pregnant because of the 
risk of fetal and neonatal morbidity and mortality associated 
with drugs that act on the RAS.60
To evaluate the safety and tolerability of aliskiren, White 
and colleagues pooled safety data from 12 randomized 
  clinical trials of aliskiren involving 12,188 patients with 
hypertension.16 The studies included in this analysis were 
categorized as short term (8 weeks) placebo controlled or 
long term (26–52 weeks) active controlled. In the short-term 
studies (n = 8862), AEs were reported by 33.6%, 31.6%, and 
36.8% of patients treated with aliskiren 150 mg, aliskiren 
300 mg, and placebo, respectively. Serious AEs occurred 
in 0.4%, 0.5%, and 0.7% of patients treated with aliskiren 
150 mg, aliskiren 300 mg, and placebo, respectively. The 
rate of discontinuation due to AEs was #1.4% for both 
aliskiren doses and 2.6% for placebo. In the long-term 
studies (n = 3326), AEs were reported by 33.7% of patients 
treated with aliskiren 150 mg, 43.2% of patients treated 
with aliskiren 300 mg, 60.1% of patients treated with ACE 
inhibitors, 53.9% of patients treated with ARBs, and 48.9% 
of patients treated with thiazide diuretics. Serious AEs 
occurred in 3.4% of patients treated with aliskiren (both 
doses), compared with 2.4%, 8.4%, and 1.7% of patients 
treated with ACE inhibitors, ARBs, and thiazide diuret-
ics, respectively. The rate of discontinuation due to AEs 
was 3.2%, 1.7%, 6.9%, 6.5%, and 3.3% for the aliskiren 
150-mg, aliskiren 300-mg, ACE inhibitors, ARBs, and thi-
azide diuretics groups, respectively. Incidences of AEs of 
special interest (possibly related to RAS agents) are listed 
in Table 6. The incidence of cough was low for all aliskiren Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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treatment groups; it was similar to that of placebo in the 
short-term studies and lower than ACE inhibitors in the 
long-term studies. In the short-term studies, the incidence 
of abnormalities in prespecified laboratory values was low 
and similar to placebo. In the aliskiren 150-mg, aliskiren 
300-mg, and placebo groups, respectively, 0.9%, 1.6%, and 
1.3% of patients had serum potassium levels .5.5 mEq/L 
at any visit during the double-blind treatment period. In the 
long-term studies, 5.7% of patients treated with aliskiren 
300 mg had serum potassium levels .5.5 mEq/L, compared 
with 1.9% to 3.7% of patients in all other treatment groups. 
Overall, the safety profile of aliskiren was similar to that of 
placebo and similar or superior to other antihypertensive 
agents.16
Conclusions
ARBs are well tolerated, with a class safety profile similar 
to that of placebo and no known class-specific AEs. Results 
from meta-analyses evaluating the risks of myocardial 
infarction or cancer associated with ARBs have been 
inconsistent, and caution should be used when evaluating 
the results of these analyses because even the most well 
designed and carefully executed meta-analyses have sig-
nificant   limitations. Evidence from landmark, randomized 
clinical trials published to date does not suggest a link 
between ARBs and an increased risk of cancer or myocar-
dial infarction. The FDA’s position on ARB use is that the 
benefits of these drugs outweigh their risks, and the FDA 
has not concluded that ARBs increase the risk of cancer. 
The DRI aliskiren is also a well-tolerated antihypertensive 
drug, with a safety profile that is similar to that of placebo 
and similar or superior to those of other antihypertensive 
drugs. As part of the aliskiren ASPIRE HIGHER clinical 
trials program, studies are ongoing in patients with known 
cardiovascular or renal risk factors and results of these tri-
als will provide additional data on the overall tolerability 
profile of aliskiren.1
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